NCT02523495

Brief Summary

Through clinical observation and data statistics, conclude the clinical outcome of target therapy in metastasis colorectal cancer and explore some biomarkers that relate to target therapy.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2012

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2012

Completed
3.2 years until next milestone

First Submitted

Initial submission to the registry

August 4, 2015

Completed
10 days until next milestone

First Posted

Study publicly available on registry

August 14, 2015

Completed
4.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2020

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2022

Completed
Last Updated

August 7, 2018

Status Verified

August 1, 2018

Enrollment Period

8.1 years

First QC Date

August 4, 2015

Last Update Submit

August 5, 2018

Conditions

Neoplasms, Therapy-Associated

Keywords

Molecular Targeted Therapymetastasis colorectal cancerbiomarker

Outcome Measures

Primary Outcomes (1)

  • overall survival

    5 years

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Metastasis colorectal cancer patients in Chinese Han population

You may qualify if:

  • Metastasis colorectal cancer confirmed by histologically and radiography
  • Receive target therapy over half a year
  • Have a measurable lesions

You may not qualify if:

  • \. A history of other malignant tumors in five years

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Huazhong University of Science and Technology

Wuhan, Hubei, 430000, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Whole blood

MeSH Terms

Conditions

Neoplasms, Second Primary

Condition Hierarchy (Ancestors)

Neoplasms

Central Study Contacts

Yuan Xianglin, Professional

CONTACT

13667241722yxl@medmail.com.cn

Zhao Ben, Master

CONTACT

15071206621zhaoben0609@163.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
5 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor, Chief physician

Study Record Dates

First Submitted

August 4, 2015

First Posted

August 14, 2015

Study Start

June 1, 2012

Primary Completion

July 1, 2020

Study Completion

July 1, 2022

Last Updated

August 7, 2018

Record last verified: 2018-08

Locations

CN(1)